On the Rebound: How Combined-Cycle Power Plants Reshape Electric Fossil Fuel Demand
The Energy Journal · 2026-07 · 47 (4) · 113-132
DOI: 10.1177/01956574261438744 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Energy Journal, online erschienen am 10.04.2026. Verfasst von Hillard G. Huntington. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Electrification with more energy-efficient combined-cycle power plants has been featured prominently in the US energy system for multiple decades. This empirical analysis estimates the role of efficiency improvements for natural gas plants on the use of coal and natural gas for U.S. electric generation. The estimates are based upon actual technical improvements in energy efficiency (measured as declining heat rates) rather than strong economic priors like price elasticities. The estimates underscore that the meaning of the rebound effect will have an important policy content with very different interpretations. Natural gas heat rates improved by 16.3% since 2001. Over the same period, these improvements caused a 21.8% drop in natural gas use, a 6.6% decline in fossil fuel use, and a 2.0% decrease in carbon dioxide emissions associated with these fuel use adjustments. JEL Classification: Q41, Energy: Demand and Supply; Prices; O33, Technological Change: Choices and Consequences; Diffusion Processes
Zitieren
APA
Huntington, H. G. (2026). On the Rebound: How Combined-Cycle Power Plants Reshape Electric Fossil Fuel Demand. The Energy Journal, 47(4), 113-132. https://doi.org/10.1177/01956574261438744
Vancouver
Huntington HG. On the Rebound: How Combined-Cycle Power Plants Reshape Electric Fossil Fuel Demand. The Energy Journal. 2026;47(4):113-132. doi:10.1177/01956574261438744
BibTeX
@article{Huntington2026,
author = {Huntington, Hillard G.},
title = {On the Rebound: How Combined-Cycle Power Plants Reshape Electric Fossil Fuel Demand},
journal = {The Energy Journal},
year = {2026},
volume = {47},
number = {4},
pages = {113--132},
doi = {10.1177/01956574261438744}
}
EUVIMED